Everbright Biotech -B (09606.HK): Fully exercised the excess rights issue.

Wisdom Finance APP news, Amgen-B (09606.HK) announced that the joint representative (on behalf of itself and representing international underwriters) has fully exercised the oversubscription rights as described in the prospectus on May 6, 2025, involving a total of 2.5998 million shares, accounting for approximately 15% of the total number of shares available for subscription under the global offering (taking into account the exercise of the over-allotment option but before exercising the oversubscription rights).